Company Profile
Lipocine Inc. Stock Price, News & Analysis
- Ticker:
- LPCN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.13 USD (-1.84%)
Close
Last updated: August 6, 2026
18.5M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, LPCN closed down 1.84% at $2.13. No new same-company headline was identified in the current news window.
Company overview
Oral Drug-Delivery Platform
Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.
LPCN 1154
LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future development path uncertain.
Product-Focused Development Model
The company applies its formulation technology to established active pharmaceutical ingredients, seeking differentiated dosing, convenience or pharmacokinetic profiles in endocrine and neuropsychiatric indications.
Future catalysts
Lipocine’s catalysts are TLANDO and the hormone-therapy / men’s-health franchise, plus any strategic update that clarifies the commercial path. The stock will care about recurring prescription demand.
Recent news
- 01
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Source: Lipocine Inc.
- 02
Lipocine Appoints Michael J. Grissinger to Board of Directors
Source: Lipocine Inc.
- 03
- 04
- 05
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Source: Lipocine Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lipocine Inc. (LPCN)?
Lipocine Inc. (LPCN) most recently closed at 2.13 USD, a -1.84% move versus the previous session.
What is the market cap of Lipocine Inc. (LPCN)?
Lipocine Inc. currently has a market capitalization of 18.5M USD on BioPharmSignal.
What does Lipocine Inc. do?
Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth. LPCN 1154 LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future...
On which exchange is LPCN stock listed?
Lipocine Inc. (LPCN) is associated with NASDAQ, United States, Biopharma.
What is Oral?
Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.
Which conditions is Lipocine Inc. targeting with Oral?
Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth. LPCN 1154 LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the program's future...
How does Lipocine Inc. describe recent progress with Oral?
Lipocine’s catalysts are TLANDO and the hormone-therapy / men’s-health franchise, plus any strategic update that clarifies the commercial path. The stock will care about recurring prescription demand.
What is Drug-Delivery?
Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth.